Mainz Biomed (MYNZ) announced that its pancreatic cancer project will receive public funding from the Investitions- und Strukturbank Rheinland-Pfalz, the development bank of the German federal state of Rheinland-Pfalz. Under the ISB’s Innovation and Technology Support Program, the state will fund up to 50% of the project’s total costs. This direct governmental support represents a strong endorsement of the scientific and societal value of Mainz Biomed’s non-invasive, blood-based screening test for the early detection of pancreatic cancer and will accelerate its development.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYNZ:
- Promising Advancements in Cancer Diagnostics Propel Mainz Biomed B.V. to a Buy Rating
- Mainz initiates feasibility study of biomarker panel in PancAlert project
- Mainz Biomed N.V. Shareholders Approve Key Proposals at Annual Meeting
- Mainz Biomed N.V. Secures $4 Million Through Securities Offering
- Mainz Biomed prices $4.0M offering of common stock at $2.00 per unit